Association of serum 8-hydroxy-2′-deoxyguanosine levels with the presence and severity of coronary artery disease

Coronary Artery Disease

Volumn 22, Issue 4, 2011, Pages 223-227

  Xiang, Fei ^a   Shuanglun, Xie ^a   Jingfeng, Wang ^a   Ruqiong, Nie ^a   Yuan, Zhang ^b   Yongqing, Lin ^a   Jun, Zhang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Liuhuaqiao Hospital   (China)

Author keywords

8 hydroxy 20 deoxyguanosine; atherosclerosis; coronary artery disease; oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DEOXYGUANOSINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 79955643047     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328344b615     Document Type: Article

References (27)

1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000; 87:840-844.
2. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84:1381-1478. (Pubitemid 39302636)
3. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993; 98:1-9. (Pubitemid 23010418)
4. Therond P, Bonnefont-Rousselot D, Davit-Spraul A, Conti M, Legrand A. Biomarkers of oxidative stress: An analytical approach. Curr Opin Clin Nutr Metab Care 2000; 3:373-384.
5. Redó n J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41:1096-1101. (Pubitemid 36548609)
6. Calişkan-Can E, Firat H, Ardiç S, Simşek B, Torun M, Yardim-Akaydin S. Increased levels of 8-hydroxydeoxyguanosine and its relationship with lipid peroxidation and antioxidant vitamins in lung cancer. Clin Chem Lab Med 2008; 46:107-112.
7. Harman SM, Liang L, Tsitouras PD, Gucciardo F, Heward CB, Reaven PD, et al. Urinary excretion of three nucleic acid oxidation adducts and isoprostane F(2)alpha measured by liquid chromatography-mass spectrometry in smokers, ex-smokers, and nonsmokers. Free Radic Biol Med 2003; 35:1301-1309. (Pubitemid 37357255)
8. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-20-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2009; 27:120-139.
9. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002; 106:927-932. (Pubitemid 34925325)
10. Botto N, Masetti S, Petrozzi L, Vassalle C, Manfredi S, Biagini A, et al. Elevated levels of oxidative DNA damage in patients with coronary artery disease. Coron Artery Dis 2002; 13:269-274. (Pubitemid 35397528)
11. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51:606. (Pubitemid 13187192)
12. Mutlu-Turkoglu U, Akalin Z, Ilhan E, Yilmaz E, Bilge A, Nisanci Y, et al. Increased plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in patients with angiographically defined coronary artery disease. Clin Biochem 2005; 38:1059-1065. (Pubitemid 41797744)
13. Wang B, Pan J, Wang L, Zhu H, Yu R, Zou Y. Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease. Atherosclerosis 2006; 184:425-430. (Pubitemid 43049730)
14. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002; 162:221-225. (Pubitemid 34327362)
15. De Flora S, Izzotti A, Walsh D, Degan P, Petrilli GL, Lewtas J. Molecular epidemiology of atherosclerosis. FASEB J 1997; 11:1021-1031. (Pubitemid 27425904)
16. Nagayoshi Y, Kawano H, Hokamaki J, Uemura T, Soejima H, Kaikita K, et al. Differences in oxidative stress markers based on the aetiology of heart failure: Comparison of oxidative stress in patients with and without coronary artery disease. Free Radic Res 2009; 43:1159-1166.
17. Andreassi MG, Botto N. DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc Med 2003; 13:270-275. (Pubitemid 37159391)
18. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci U S A 1973; 70:1753-1756.
19. Matturri L, Cazzullo A, Turconi P, Lavezzi AM, Vandone PL, Gabrielli L, et al. Chromosomal alterations in atherosclerotic plaques. Atherosclerosis 2001; 154:755-761. (Pubitemid 32232175)
20. Hatzistamou J, Kiaris H, Ergazaki M, Spandidos DA. Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 1996; 225:186-190. (Pubitemid 26285417)
21. Botto N, Rizza A, Colombo MG, Mazzone AM, Manfredi S, Masetti S, et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 2001; 493:23-30. (Pubitemid 32539427)
22. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J Biol Chem 1992; 267:166-172.
23. Kouda K, Nakamura H, Fan W, Horiuchi K, Takeuchi H. The relationship of oxidative DNA damage marker 8-hydroxydeoxyguanosine and glycoxidative damage marker pentosidine. Clin Biochem 2001; 34:247-250. (Pubitemid 32537677)
24. Voghel G, Thorin-Trescases N, Farhat N, Nguyen A, Villeneuve L, Mamarbachi AM, et al. Cellular senescence in endothelial cells from atherosclerotic patients is accelerated by oxidative stress associated with cardiovascular risk factors. Mech Ageing Dev 2007; 128:662-671. (Pubitemid 350299049)
25. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004; 256:308-315. (Pubitemid 39304342)
26. Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2009; 16:539-545.
27. Ono H, Minatoguchi S, Watanabe K, Yamada Y, Mizukusa T, Kawasaki H, et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res 2008; 31:271-279. (Pubitemid 351461107)